• <input id="ycg2u"></input>
    <legend id="ycg2u"></legend>
    <strong id="ycg2u"><u id="ycg2u"></u></strong>
  • Enable Accessibility Enable Accessibility

    Information on the Recall of NATPARA in the US

    Takeda is committed to the hypoparathyroidism community and continues to work with the FDA on both short- and long-term solutions to bring NATPARA back to patients, which remains our highest priority. We will continue to work diligently on this issue and keep patients and healthcare providers informed of our progress.

    If you are a patient with questions about the U.S. recall of NATPARA, please reach out to our OnePath patient services team at 866-888-0660. Healthcare providers with questions should call 800-828-2088.

    All of Takeda’s public communications regarding the recall and subsequent actions can be found here:

    September 15

    July 12

    June 14

    May 25

    April 16

    April 12

    April 9

    March 31

    February 8

    December 23

    December 18

    November 17

    October 20

    January 21

    November 22

    October 9

    October 9

    Takeda’s Letter to Patients about the US Class I Recall of NATPARA

    The above letter has been sent to all NATPARA patients. However, all patients participating in the Special Use Program will receive a separate letter addressing their own individual circumstances. This Recall does not apply to single-use cartridges provided to participants in the NATPARA Special Use Program.

    September 26

    September 25

    September 24

    September 24

    September 16

    September 13

    September 6

    September 5